Asunto(s)
Actinomicosis Cervicofacial/diagnóstico , Edema/diagnóstico , Cuello/patología , Infecciones por Pasteurellaceae/diagnóstico , Pérdida de Peso , Actinomicosis Cervicofacial/complicaciones , Aggregatibacter actinomycetemcomitans/aislamiento & purificación , Trastornos Relacionados con Cocaína/complicaciones , Diagnóstico Diferencial , Edema/patología , Hepatitis C/complicaciones , Dependencia de Heroína/complicaciones , Humanos , Enfermedad Relacionada con Inmunoglobulina G4/diagnóstico , Masculino , Persona de Mediana Edad , Infecciones por Pasteurellaceae/complicaciones , Enfermedades Torácicas/complicaciones , Enfermedades Torácicas/diagnóstico , Enfermedades Torácicas/microbiología , Tabaquismo/complicacionesRESUMEN
Thoracic endometriosis (TE) syndrome is a clinical condition known as an extrapelvic form of endometriosis with the presence of functioning endometrial tissue involving lung parenchyma, pleura, chest wall, or diaphragm. In an effort to obtain an endometriosis ex vivo model, we established the spontaneously growing TH-EM1 cell line from endometriotic implants in lung parenchyma from a woman with TE. Maintained in long-term culture, the cells grew as large mesenchymal-like cells with a doubling time between 5 and 6 days. Treatment with medroxyprogesterone acetate (10-7 mol/L) inhibited the TH-EM1 cells growth and induced morphological changes to an epithelial-like cells. Strong expression of the nuclear estrogen receptors, progesterone receptors, and erytropoietin receptors were found in both the pulmonary implant and the TH-EM1 cells by immunohistochemical analysis. Consistent immunoreactivity of TH-EM1 cells for CD9, CD13, CD73, CD90, CD105, and CD157 was revealed by flow cytometry. Likewise, the embryonic markers, SRY-box 2 (SOX-2) and the Nanog molecules, were detected in 76% and 52% of the cells, while fetal hemoglobin and a-globin were detected in 76% and 65% of TH-EM1 cells, respectively. By RHG banding, normal metaphases were observed, while the microarray chromosomal analysis showed gains of DNA sequences located on the segments 8p23.1, 11p15.5, and 12p11.23. The described in vitro cellular model can serve as a useful tool to study the pathogenesis of endometriosis and to improve the knowledge of molecular mechanisms controlling the endometriotic cell dissemination potential.
Asunto(s)
Endometriosis/genética , Endometriosis/patología , Endometrio/patología , Células del Estroma/patología , Enfermedades Torácicas/metabolismo , Enfermedades Torácicas/patología , Adulto , Técnicas de Cultivo de Célula/métodos , Proliferación Celular/fisiología , Diafragma/metabolismo , Diafragma/patología , Endometriosis/metabolismo , Endometrio/metabolismo , Femenino , Humanos , Células del Estroma/metabolismo , Enfermedades Torácicas/genéticaRESUMEN
Thoracic endometriosis (TE) syndrome is a clinical condition known as an extrapelvic form of endometriosis with the presence of functioning endometrial tissue involving lung parenchyma, pleura, chest wall, or diaphragm. In an effort to obtain an endometriosis ex vivo model, we established the spontaneously growing TH-EM1 cell line from endometriotic implants in lung parenchyma from a woman with TE. Maintained in long-term culture, the cells grew as large mesenchymal-like cells with a doubling time between 5 and 6 days. Treatment with medroxyprogesterone acetate (10-7 mol/L) inhibited the TH-EM1 cells growth and induced morphological changes to an epithelial-like cells. Strong expression of the nuclear estrogen receptors, progesterone receptors, and erytropoietin receptors were found in both the pulmonary implant and the TH-EM1 cells by immunohistochemical analysis. Consistent immunoreactivity of TH-EM1 cells for CD9, CD13, CD73, CD90, CD105, and CD157 was revealed by flow cytometry. Likewise, the embryonic markers, SRY-box 2 (SOX-2) and the Nanog molecules, were detected in 76% and 52% of the cells, while fetal hemoglobin and α-globin were detected in 76% and 65% of TH-EM1 cells, respectively. By RHG banding, normal metaphases were observed, while the microarray chromosomal analysis showed gains of DNA sequences located on the segments 8p23.1, 11p15.5, and 12p11.23. The described in vitro cellular model can serve as a useful tool to study the pathogenesis of endometriosis and to improve the knowledge of molecular mechanisms controlling the endometriotic cell dissemination potential.
RESUMEN
Objetivos: Evaluar el papel de la biopsia de mapeo guiada por plantilla transperineal (TTMB) en la determinación de la estrategia de manejo en pacientes con cáncer de próstata (CaP) de bajo riesgo. Métodos: Evaluamos retrospectivamente 169 pacientes que se sometieron a TTMB en nuestra institución entre febrero de 2008 y junio de 2011. Noventa y ocho de ellos albergaban CaP indolente definido como: antígeno prostático específico <10ng/ml, puntuación de Gleason 6 o menos, estadio clínico T2a o menos, enfermedad unilateral y un máximo de un tercio de núcleos positivos en la primera biopsia y <50% del núcleo en cuestión. Se analizaron los resultados TTMB para clasificación al alza y estadificación al alza de puntuación de Gleason en comparación con las biopsias iniciales de ecografía transrectal (ETR) y su influencia en el cambio en las decisiones de tratamiento. Resultados: TTMB detectó el cáncer en 64 (65%) pacientes. La clasificación al alza y estadidificación al alza se observaron en el 33% (n=21), 12% (n=8) y 7% (n=5), respectivamente, de los cánceres detectados. Las características de la enfermedad fueron similares a la ETR inicial en 30 (48%) pacientes y TTMB fue negativa en 34 (35%) pacientes. El volumen de la próstata fue significativamente menor en los pacientes con clasificación al alza y/o estadificación al alza observado en TTMB (45,4 vs 37,9; p=0,03). Los resultados de TTMB influenciaron en el 73,5% de los pacientes clasificación al alza y/o estadificación al alza para recibir tratamiento radical, mientras que el 81% de los pacientes con estadio y/o grado sin modificar continuaron la vigilancia activa o terapia focal. Conclusiones: En los pacientes con CaP de bajo riesgo diagnosticados por ETR, una posterior TTMB demostró clasificación al alza y/o estadificación al alza en aproximadamente un tercio de los pacientes, y dio lugar a un cambio final en la decisión de tratamiento
Objectives: To evaluate the role of Transperineal Template guided Mapping Biopsy (TTMB) in determining the management strategy in patients with low risk prostate cancer (PCa). Methods: We retroscpectively evaluated 169 patients who underwent TTMB at our institution from February 2008 to June 2011. Ninety eight of them harbored indolent PCa defined as: Prostate Specific Antigen < 10ng/ml, Gleason score 6 or less, clinical stage T2a or less, unilateral disease and a maximum of one third positive cores at first biopsy and < 50% of the core involved. TTMB results were analyzed for Gleason score upgrading and upstaging as compared to initial TransRectal UltraSound (TRUS) biopsies and its influence on the change in the treatment decisions. Results: TTMB detected cancer in 64 (65%) patients. The upgrade, upstage and both were noted in 33% (n = 21), 12% (n = 8) and 7% (n = 5) respectively of the detected cancers. The disease characteristics was similar to initial TRUS in 30 (48%) patients and TTMB was negative in 34 (35%) patients. Prostate volume was significantly smaller in patients with upgrade and/or upstage noted at TTMB (45.4 vs 37.9; P = .03). TTMB results influenced 73.5% of upgraded and/or upstaged patients to receive radical treatment while 81% of the patients with unmodified stage and/or grade continued active surveillance or focal therapy. Conclusions: In patients with low risk PCa diagnosed by TRUS, subsequent TTMB demonstrated cancer upgrade and/or upstage in about one-third of the patients and resulted in eventual change in treatment decision
Asunto(s)
Humanos , Masculino , Anciano , Persona de Mediana Edad , Toma de Decisiones Clínicas , Neoplasias de la Próstata/patología , Ultrasonido Enfocado Transrectal de Alta Intensidad , Próstata/patología , Estudios Retrospectivos , Medición de Riesgo , Peritoneo , Resección Transuretral de la Próstata/métodos , Biopsia Guiada por Imagen/métodosRESUMEN
OBJECTIVES: To evaluate the role of Transperineal Template guided Mapping Biopsy (TTMB) in determining the management strategy in patients with low risk prostate cancer (PCa). METHODS: We retroscpectively evaluated 169 patients who underwent TTMB at our institution from February 2008 to June 2011. Ninety eight of them harbored indolent PCa defined as: Prostate Specific Antigen<10ng/ml, Gleason score 6 or less, clinical stage T2a or less, unilateral disease and a maximum of one third positive cores at first biopsy and<50% of the core involved. TTMB results were analyzed for Gleason score upgrading and upstaging as compared to initial TransRectal UltraSound (TRUS) biopsies and its influence on the change in the treatment decisions. RESULTS: TTMB detected cancer in 64 (65%) patients. The upgrade, upstage and both were noted in 33% (n=21), 12% (n=8) and 7% (n=5) respectively of the detected cancers. The disease characteristics was similar to initial TRUS in 30 (48%) patients and TTMB was negative in 34 (35%) patients. Prostate volume was significantly smaller in patients with upgrade and/or upstage noted at TTMB (45.4 vs 37.9; P=.03). TTMB results influenced 73.5% of upgraded and/or upstaged patients to receive radical treatment while 81% of the patients with unmodified stage and/or grade continued active surveillance or focal therapy. CONCLUSIONS: In patients with low risk PCa diagnosed by TRUS, subsequent TTMB demonstrated cancer upgrade and/or upstage in about one-third of the patients and resulted in eventual change in treatment decision.
Asunto(s)
Toma de Decisiones Clínicas , Próstata/patología , Neoplasias de la Próstata/patología , Anciano , Humanos , Biopsia Guiada por Imagen/métodos , Masculino , Persona de Mediana Edad , Peritoneo , Estudios Retrospectivos , Medición de RiesgoRESUMEN
Endobronchial ultrasonography (EBUS) is a recent mini-invasive technique allowing transbronchial needle aspiration (TBNA) of mediastinal lymph nodes as well as peribronchial lesions. EBUS was initially developed for lung cancer mediastinal staging. Over the years, indications for EBUS have been progressively extended to the scope of inflammatory disorders, mediastinal lymphomas, and infectious diseases. Particularly in immunosuppressed patients, including HIV-infected patients, EBUS allows the diagnosis of several diseases that involve the mediastinum, avoiding invasive surgical explorations such as mediastinoscopy or thoracoscopy. This review aims at discussing the technical aspects, and specifies indications, results, and limits of EBUS for the internist.
Asunto(s)
Broncoscopía/métodos , Medicina Interna/métodos , Enfermedades Respiratorias/diagnóstico , Ultrasonografía Intervencional , Broncoscopía/estadística & datos numéricos , Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico , Humanos , Neoplasias del Mediastino/diagnóstico , Neoplasias del Mediastino/patología , Mediastinoscopía , Estadificación de Neoplasias/métodos , Enfermedades Respiratorias/diagnóstico por imagen , Enfermedades Respiratorias/patología , Ultrasonografía Intervencional/estadística & datos numéricosRESUMEN
BACKGROUND: To assess the impact of the degree of extraprostatic extension (EPE) on biochemical recurrence (BCR) and utility of the original Epstein's criteria to define EPE in a cohort of pT3aN0 without positive surgical margin (PSM). METHODS: A two-center retrospective analysis was performed on data from 490 pT3aN0 patients who underwent radical prostatectomy between 2000 and 2012. Patients with neoadjuvant and/or adjuvant therapy, detectable PSA and PSM were excluded. Our pathologists used Epstein's criteria to report the degree of EPE. When pathology reports did not reflect the terms 'focal' or 'established' (non-focal), slides were analyzed by a single genitourinary pathologist for final evaluation. The end point was defined by BCR. RESULTS: Selection criteria yielded 247 patients. Mean follow-up was 56.3±4.6 months; mean age at surgery was 62.5 years. Sixty-one (24.7%) patients experienced BCR during follow-up. Patients with focal extension had a 5-year recurrence-free survival of 89% versus 80% for those with non-focal extension (P=0.0018). In multivariate analysis, both pathologic Gleason score (hazard ratio 2.5; 95% confidence interval 1.4-4.5; P=0.002) and the extent of EPE (hazard ratio 1.8; 95% confidence interval 1.1-3.5; P=0.029) were significant predictors of BCR. CONCLUSIONS: The extent of EPE is an independent predictor of BCR in pT3aN0 prostate cancer without PSM. This study reinforces the utility of the subjective Epstein approach already adopted by most pathologists for quantification of the extent of EPE.
Asunto(s)
Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/mortalidad , Anciano , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Metástasis Linfática , Masculino , Márgenes de Escisión , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Pronóstico , Antígeno Prostático Específico , Prostatectomía , Neoplasias de la Próstata/cirugía , Estudios Retrospectivos , Carga TumoralRESUMEN
CD245 is a human surface antigen expressed on peripheral blood lymphocytes, initially delineated by two monoclonal antibodies DY12 and DY35. Until now, CD245 molecular and functional characteristics remained largely unknown. We combined immunological and proteomic approaches and identified CD245 as the unconventional myosin 18A, a highly conserved motor enzyme reported as a receptor for the surfactant protein A (SP-A), that plays a critical role in cytoskeleton organization and Golgi budding. We report that the recruitment of CD245 strongly enhanced NK cell cytotoxicity. Further, we show that the enhancement of the NK lymphocytes killing ability toward CD137-ligand expressing target cells could result from the induction of CD137 expression following CD245 engagement. The SP-A receptor could therefore represent a novel and promising target in cancer immunotherapy.
RESUMEN
INTRODUCTION: Bronchogenic cysts are congenital malformations that are usually located in the mediastinum. Intrapulmonary location is rare. OBSERVATION: Four cases of intrapulmonary bronchogenic cysts are reported in order to discuss their clinical and radiological presentation and their treatment. CONCLUSION: Intrapulmonary bronchogenic cysts diagnostic is often missed. This condition must however be known so as to foresee a resection in order to prevent a potential complication.
Asunto(s)
Quiste Broncogénico/patología , Pulmón/patología , Adulto , Anciano , Quiste Broncogénico/diagnóstico por imagen , Quiste Broncogénico/cirugía , Broncoscopía , Diagnóstico Diferencial , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/cirugía , Masculino , Radiografía Torácica , Adulto JovenRESUMEN
INTRODUCTION: Schwannomas are a form of rare tumor, arising from neural tissue and representing 2 % of mediastinal tumors. They are usually located in the posterior mediastinum, most often in the paravertebral gutters and typically appended to intercostal nerves. CASE REPORTS: We report two cases of unusual mediastinal schwannomas, appended to the vagus nerve. The schwannoma was located in the subcarinal region in the first case and in the right para-tracheal region in the second case. The lesions were thought to be bronchogenic cysts preoperatively in both cases because of a cystic appearance on preoperative CT scan and endobronchial ultrasonography. A surgical approach was adopted to remove the tumors. Video-assisted thoracoscopy was used in one case and robotic-assisted surgery in the second case, without any complication, allowing for complete resection and to establish a certain pathological diagnosis. CONCLUSION: Despite this location and cystic presentation being unusual, schwannoma should be considered as a possible cause of cystic lesions in the mediastinum. Minimally invasive surgery allows for complete resection and definitive pathological diagnosis.
Asunto(s)
Neoplasias de los Nervios Craneales/diagnóstico , Neoplasias del Mediastino/diagnóstico , Neurilemoma/diagnóstico , Enfermedades del Nervio Vago/diagnóstico , Nervio Vago/patología , Anciano , Neoplasias de los Nervios Craneales/patología , Neoplasias de los Nervios Craneales/cirugía , Femenino , Humanos , Masculino , Neoplasias del Mediastino/patología , Neoplasias del Mediastino/cirugía , Mediastino/patología , Mediastino/cirugía , Persona de Mediana Edad , Neurilemoma/patología , Neurilemoma/cirugía , Procedimientos Quirúrgicos Robotizados , Nervio Vago/cirugía , Enfermedades del Nervio Vago/cirugíaRESUMEN
BACKGROUND: HER2 is overexpressed in 10 to 20% of gastro-esophageal adenocarcinoma (GE-ADK), and is a target for trastuzumab in metastatic patients. We conducted a study to compare HER2 expression between diagnostic biopsies (DBs) and surgical specimens (SSs) of GE-ADK, and to determine the influence of non-trastuzumab containing neoadjuvant chemotherapy (NAC) on this expression. PATIENTS AND METHODS: Pathological specimens from biopsies of 228 patients operated on between 2004 and 2011 were collected. Two cohorts treated (n = 141) or not (n = 87) with a NAC were constituted. Two blind independent pathological HER2 analyses on DB and on SS were carried out using immunohistochemistry (IHC) and colorimetric in situ hybridization (CISH). HER-2 overexpression (HER2+) was defined by a score 3+ in IHC, or 2+ with a positive CISH test, according to the specific HER2 scoring guidelines for GE-ADK. RESULTS: Paired HER2 status could be determined for 218 out of the 228 patients (95.6%). HER2+ rates were 13.3% on DB (29/218) and 14.7% on SS (32/218). HER2+ tumors were mainly cardial or esophageal adenocarcinomas, with a well-differentiated, intestinal histological type. HER2 status differed between DB and SS in 6% of cases. When DB analyses were added to SS analyses, the relative increase in HER2+ cases was 13.5% (17.1% for patients with NAC and 23.5% for patients with histological response to NAC, versus 7.1% for patients without NAC, P = 0.4, NS). Differences between DB and SS HER2 expression could be explained by intratumoral heterogeneity and by a HER2 expression decrease in SS after NAC in responding patients possibly due to a higher chemosensitivity of HER2-positive clones. CONCLUSION: The determination of HER2 status on DB provides results that complete those obtained with SS. Combining the analysis of DB and of SS enables to optimize the selection of trastuzumab-eligible patients in case of metastatic relapse, and particularly in previously NAC-responding patients.
Asunto(s)
Adenocarcinoma/metabolismo , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias Esofágicas/metabolismo , Receptor ErbB-2/metabolismo , Neoplasias Gástricas/metabolismo , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Quimioterapia Adyuvante , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Selección de Paciente , Método Simple Ciego , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/patología , TrastuzumabRESUMEN
BACKGROUND: Ex vivo colospheres have been previously characterised as a colorectal cancer (CRC) well-rounded multicellular model, exclusively formed by carcinoma cells, and derived from fresh CRC tissue after mechanical dissociation. The ability to form colospheres was correlated with tumour aggressiveness. Their three-dimensional conformation prompted us to further investigate their potential interest as a preclinical cancer tool. METHODS: Patient-derived CRC xenografts were used to produce numerous colospheres. Mechanism of formation was elucidated by confocal microscopy. Expression analysis of a panel of 64 selected cancer-related genes by real-time qRT-PCR and hierarchical clustering allowed comparison of colospheres with parent xenografts. In vitro and in vivo assays were performed for migration and chemosensitivity studies. RESULTS: Colospheres, formed by tissue remodelling and compaction, remained viable several weeks in floating conditions, escaping anoikis through their strong cell-cell interactions. Colospheres matched the gene expression profile of the parent xenograft tissue. Colosphere-forming cells migrated in collagen I matrix and metastasised when subrenally implanted in nude mice. Besides, the colosphere responses to 5-fluorouracil and irinotecan, two standard drugs in CRC, reproduced those of the in vivo original xenografts. CONCLUSION: Colospheres closely mimic biological characteristics of in vivo CRC tumours. Consequently, they would be relevant ex vivo CRC models.
Asunto(s)
Neoplasias Colorrectales/patología , Animales , Camptotecina/análogos & derivados , Camptotecina/farmacología , Línea Celular Tumoral , Movimiento Celular/fisiología , Supervivencia Celular/fisiología , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Fluorouracilo/farmacología , Humanos , Irinotecán , Ratones , Ratones Desnudos , Ratones SCID , Microscopía Confocal , Trasplante de Neoplasias , Distribución Aleatoria , Reacción en Cadena en Tiempo Real de la Polimerasa , Esferoides Celulares/patología , Trasplante Heterólogo , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: The need to unfold the underlying mechanisms of lung cancer aggressiveness, the deadliest cancer in the world, is of prime importance. Because Fas-associated death domain protein (FADD) is the key adaptor molecule transmitting the apoptotic signal delivered by death receptors, we studied the presence and correlation of intra- and extracellular FADD protein with development and aggressiveness of non-small cell lung cancer (NSCLC). METHODS: Fifty NSCLC patients were enrolled in this prospective study. Intracellular FADD was detected in patients' tissue by immunohistochemistry. Tumours and distant non-tumoural lung biopsies were cultured through trans-well membrane in order to analyse extracellular FADD. Correlation between different clinical/histological parameters with level/localisation of FADD protein has been investigated. RESULTS: Fas-associated death domain protein could be specifically downregulated in tumoural cells and FADD loss correlated with the presence of extracellular FADD. Indeed, human NSCLC released FADD protein, and tumoural samples released significantly more FADD than non-tumoural (NT) tissue (P=0.000003). The release of FADD by both tumoural and NT tissue increased significantly with the cancer stage, and was correlated with both early and late steps of the metastasis process. CONCLUSION: The release of FADD by human NSCLC could be a new marker of poor prognosis as it correlates positively with both tumour progression and aggressiveness.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Neoplasias Pulmonares/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Carcinoma de Pulmón de Células no Pequeñas/patología , Progresión de la Enfermedad , Espacio Extracelular/metabolismo , Femenino , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Pronóstico , Estudios ProspectivosAsunto(s)
Adenocarcinoma Mucinoso/cirugía , Neoplasias de los Genitales Masculinos/cirugía , Vesículas Seminales/cirugía , Adenocarcinoma Mucinoso/complicaciones , Adenocarcinoma Mucinoso/diagnóstico , Adenocarcinoma Mucinoso/tratamiento farmacológico , Adenocarcinoma Mucinoso/patología , Quimioterapia Adyuvante , Diagnóstico Diferencial , Neoplasias de los Genitales Masculinos/complicaciones , Neoplasias de los Genitales Masculinos/diagnóstico , Neoplasias de los Genitales Masculinos/tratamiento farmacológico , Neoplasias de los Genitales Masculinos/patología , Hematospermia/etiología , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Próstata/patología , Neoplasias de la Próstata/diagnóstico , Vesículas Seminales/patologíaRESUMEN
BACKGROUND: Immunohistochemistry has been proposed as a specific and sensitive method to identify EGFR mutations or ALK rearrangements in lung tumours. PATIENTS AND METHODS: We assessed EGFR and KRAS by direct sequencing in 154 patients with lung adenocarcinoma. ALK rearrangements were assayed by FISH and RT-PCR. Immunohistochemistry was carried out and evaluated closely following published methods using recommended monoclonal rabbit or mouse antibodies. RESULTS: Thirteen of 36 exon 19 EGFR-mutated tumours (36%)-including 12 of 22 with p.Glu746_Ala750del (55%)-were positive with the 6B6 antibody that was raised against p.Glu746_Ala750del. One hundred eleven of 114 EGFR exon 19 wild-type tumours (97%) were negative with 6B6. Four of 21 exon 21 EGFR-mutated tumours (19%)-including 4 of 17 with p.Leu858Arg (24%)-were positive with the 43B2 antibody that was raised against p.Leu858Arg. One hundred twenty-two of 124 (98%) EGFR exon 21 wild-type tumours were negative with 43B2. Two of four ALK rearrangements-including two of three with ELM4-ALK fusion transcripts-were identified with the 5A4 antibody. Eleven of 13 tumours without ALK rearrangement (85%) were negative with 5A4. CONCLUSIONS: Immunohistochemistry is a specific means for identification of EGFR mutations and ALK rearrangements. It suffers, however, from poor sensitivity.
Asunto(s)
Adenocarcinoma/genética , Receptores ErbB/genética , Neoplasias Pulmonares/genética , Mutación , Proteínas Tirosina Quinasas Receptoras/genética , Adenocarcinoma/metabolismo , Anciano , Quinasa de Linfoma Anaplásico , Receptores ErbB/metabolismo , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/metabolismo , Masculino , Persona de Mediana Edad , Proteínas de Fusión Oncogénica/genética , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas p21(ras) , Proteínas Tirosina Quinasas Receptoras/metabolismo , Fumar , Proteínas ras/genéticaRESUMEN
INTRODUCTION: Several case-series studies of major pulmonary resection (MPR) by video-assisted thoracic surgery (VATS) for non-small-cell lung cancer (NSCLC) have been published, but fully endoscopic MPR is still very rarely performed. Our objective here was to report the outcomes in 71 patients recently managed using fully endoscopic MPR for NSCLC. METHODS: From 2007 to 2009, 635 patients with NSCLC underwent MPR (pneumonectomy, lobectomy or segmentectomy). Among them, 71 (11%) had features strongly suggesting clinical stage I NSCLC and were managed by fully endoscopic MPR, with no utility incision. Lobectomy was performed in 63 patients and segmentectomy in eight patients. Conversion to thoracotomy was required in two (2.8%) patients, because of a fused fissure in one and tight pleural adhesions in the other. Radical lymphadenectomy was performed in all patients. RESULTS: Of the 69 patients managed endoscopically, none died and none experienced intraoperative complications. Mean operating time was 226±38 minutes (range, 137-307 minutes) and mean intraoperative blood loss was 111±93mL (range, 0-450mL). The final histological examination showed stage I NSCLC in 52 patients, NSCLC with node involvement in nine patients (pN1 in 6 and pN2 in 3) and other types of malignancies in eight patients. Mean number of nodes removed was 21±8 after right-sided lymphadenectomy and 23±8 after left-sided lymphadenectomy and the mean number of dissected node sites was 3 (range, 2-5). The postoperative morbidity rate was 23%. Mean postoperative hospital stay length was 6.9±2 days (range, 3-12). CONCLUSION: Fully endoscopic MPR is safe and meets the criteria for oncological surgery.
Asunto(s)
Carcinoma Broncogénico/cirugía , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Neoplasias Pulmonares/cirugía , Neumonectomía/métodos , Adulto , Anciano , Anciano de 80 o más Años , Analgesia/métodos , Analgesia/estadística & datos numéricos , Carcinoma Broncogénico/patología , Carcinoma de Pulmón de Células no Pequeñas/patología , Endoscopios , Femenino , Estudios de Seguimiento , Humanos , Tiempo de Internación , Neoplasias Pulmonares/patología , Escisión del Ganglio Linfático , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Estudios Retrospectivos , Cirugía Torácica Asistida por Video/instrumentación , Cirugía Torácica Asistida por Video/métodosRESUMEN
Congenital bronchial atresia is a rare congenital obliteration of a segmental or lobar bronchus resulting in distension of the corresponding parenchyma. It is seldom diagnosed in the adult. It may lead to infectious complications and, in the long term, to damage to the adjacent lung parenchyma. A surgical resection is necessary and it can be achieved by thoracoscopy. We report a recent series of six patients.